We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
TALTZ (Eli Lilly Australia Pty Ltd)
Product name
TALTZ
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
180 working days (255)
Active ingredients
ixekizumab
Registration type
EOI
Indication
TALTZ (injection) is now also indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately, or who are intolerant, to previous DMARD therapy. Taltz may be used as monotherapy or in combination with a conventional DMARD (e.g.methotrexate).